The potential of erythrocyte α-synuclein to differentiate dementia with Lewy bodies from Parkinson’s and Alzheimer’s diseases
The Journal of Biochemistry · 2025
DOI: 10.1093/jb/mvaf017 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Biochemistry, 2025. Verfasst von Ryosuke Amagai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry, Department of Biology, Faculty of Science, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Lewy Body Disease, Alzheimer Disease. Die Arbeit nennt 63 Literaturangaben. Gefördert von: JSPS KAKENHI.
Themen: Demenz
Abstract (Originalsprache)
Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease (AD). Early differentiation of these disorders is crucial for managing core symptoms; however, existing biomarkers remain insufficient. DLB shares motor and cognitive symptoms with Parkinson’s disease (PD), and both are classified as synucleinopathies due to abnormal α-synuclein aggregation. Although α-synuclein is predominantly expressed in the central nervous system, it is also abundant in erythrocytes. Recent studies suggest a potential link between erythrocyte-derived α-synuclein and synucleinopathy pathology. Additionally, we previously reported that both erythrocytes and circulating medium and large extracellular vesicles (m/lEVs) in plasma from healthy subjects contain full-length and C-terminally truncated α-synuclein. In this study, we found that erythrocyte α-synuclein levels were significantly lower in DLB compared to AD, PD and healthy controls. Furthermore, α-synuclein levels in circulating m/lEVs were elevated in patients with neurodegenerative diseases. These findings provide new insights into the role of peripheral α-synuclein and suggest its potential utility as a diagnostic marker for DLB. While further validation is needed, erythrocyte-derived α-synuclein may complement nuclear medicine assessments in distinguishing DLB from other neurodegenerative disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biochemistry, Department of Biology, Faculty of Science, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan.
- Department of Medical Research, Sakura Medical Center, Toho University, Shimoshizu 564-1, Sakura, Chiba 285-8741, Japan.
- Department of Exploratory Medicine on Nature, Life and Man, Faculty of Medicine, Toho University, Inagecho 5-18, Inage-ku, Chiba 263-0035, Japan.
- Division of Neurology, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu 564-1, Sakura, Chiba 285-8741, Japan. Dowakai Chiba Hospital, Hasamacho 2-508, Funabashi, Chiba 274-0822, Japan…
Förderung
- JSPS KAKENHI
Zitieren
APA
Amagai, R., Hosoi, R., Yoshioka, S., Maruyama, T., Kawai, T., Yagihashi, S., Nukada, H., Sakakibara, R., & Okado-Matsumoto, A. (2025). The potential of erythrocyte α-synuclein to differentiate dementia with Lewy bodies from Parkinson’s and Alzheimer’s diseases. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvaf017
Vancouver
Amagai R, Hosoi R, Yoshioka S, Maruyama T, Kawai T, Yagihashi S, et al. The potential of erythrocyte α-synuclein to differentiate dementia with Lewy bodies from Parkinson’s and Alzheimer’s diseases. The Journal of Biochemistry. 2025. doi:10.1093/jb/mvaf017
BibTeX
@article{Amagai2025,
author = {Amagai, Ryosuke and Hosoi, Ryunosuke and Yoshioka, Sakura and Maruyama, Taiki and Kawai, Takayuki and Yagihashi, Soroku and Nukada, Hitoshi and Sakakibara, Ryuji and Okado-Matsumoto, Ayako},
title = {The potential of erythrocyte α-synuclein to differentiate dementia with Lewy bodies from Parkinson’s and Alzheimer’s diseases},
journal = {The Journal of Biochemistry},
year = {2025},
doi = {10.1093/jb/mvaf017}
}
EUVIMED